Brief: Sio Gene Therapies Announces Granting Of FDA Fast Track Designation For Investigational Axo-Aav-Gm2 Gene Therapy
01/11/2021 11:08
Nov 1 (Reuters) - Sio Gene Therapies Inc SIOX.O :
* SIO GENE THERAPIES ANNOUNCES GRANTING OF FDA FAST TRACK
DESIGNATION FOR INVESTIGATIONAL AXO-AAV-GM2 GENE THERAPY IN
PATIENTS WITH GM2 GANGLIOSIDOSIS
* SIO GENE THERAPIES INC - ENROLLMENT ONGOING IN
REGISTRATION-ENABLING TRIAL OF AXO-AAV-GM2 IN TAY-SACHS/SANDHOFF
DISEASES
Source text for Eikon: ID:nGNX8n8zhZ
Further company coverage: SIOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results